| abstract |
The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such compounds and related pharmaceutical compositions may be used for targeted treatment of diabetic and non-diabetic gastrointestinal disorders, with minimal systemic circulation beyond the gastrointestinal tract. |